113 completed, 31 unknown, 22 recruiting, 18 terminated. 212 Phase 3, 47 Phase 2.
Follow Precursor Cell Lymphoblastic Leukemia-Lymphoma: new trials by email Literature Review of Precursor Cell Lymphoblastic Leukemia-Lymphoma trials Research Report on Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma Chidamide, Control Group - T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma | Phase 3 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 132 | 2026-08-15 | 2026-08-19 |
| A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL BLB101 for Injection, Blinatumomab for Injection - Precursor B-cell Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 212 | 2026-08-09 | 2026-07-23 |
| Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant | Phase 2 / Phase 3 | Recruiting | Bambino Gesù Hospital and Research Institute | 1000 | 2026-01-07 | 2026-10-20 |
| Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL targeted drug - Acute Lymphoblastic Leukemia | Phase 3 | Recruiting | Nanfang Hospital, Southern Medical University | 154 | 2025-10-01 | 2025-10-02 |
| Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies Cyclosporine A (CsA), Sirolimus, Ruxolitinib (JAKAVI®) - Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk | Phase 2 / Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 64 | 2025-09-03 | 2026-01-26 |
| Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL Induction Therapy Regimen, Pre-Treatment Regimen, Post-CR Treatment - Acute Lymphoblastic Leukemia, Adult | Phase 2 / Phase 3 | Recruiting | Shanxi Bethune Hospital | 50 | 2025-06-01 | 2025-07-10 |
| A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia Randomization + Blinatumomab + chemotherapy, Randomization + Standard frontline T-ALL chemotherapy backbone, Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 1200 | 2025-05-06 | 2026-02-10 |
| PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL PD-1 Inhibitors - Acute T Lymphoblastic Leukemia (T-ALL) | Phase 3 | Active not recruiting | Fujian Medical University Union Hospital | 40 | 2025-05-01 | 2026-04-21 |
| Newly-diagnosed Pediatric Ph-positive B-ALL Protocol olverembatinib - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic | Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 150 | 2025-03-28 | 2025-09-03 |
| Newly-diagnosed Pediatric T-cell ALL Protocol Venetoclax, Dasatinib, homoharringtonine - Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 610 | 2025-03-11 | 2025-08-26 |
| Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol Blinatumomab, Reinduction-2 omission, Chemo-light Maintenance 2 - Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 3000 | 2025-03-03 | 2025-08-26 |
| Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B) - Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 1800 | 2025-01-03 | 2026-07-23 |
| Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 - Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 50 | 2024-07-10 | 2025-01-01 |
| The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma Nelarabine injection - T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma | Phase 3 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 83 | 2024-05-01 | 2024-05-30 |
| Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients Haplo-cord HCT, Haplo-HCT - Acute T Cell Lymphoblastic Leukemia, Haploidentical Hematopoietic Stem Cell Transplantation | Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 146 | 2024-04-01 | 2024-04-26 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis Baricitinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 150 | 2023-12-01 | 2024-08-23 |
| A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) Olverembatinib, Investigator's choice of TKI - Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 350 | 2023-08-31 | 2026-04-30 |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Biospecimen Collection, Calaspargase Pegol, Levocarnitine - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | Children's Oncology Group | 440 | 2023-08-24 | 2026-08-21 |
Showing 20 of 212. Sign in to see all of them.
Leukemia (63) · Leukemia, Myeloid, Acute (61) · Burkitt Lymphoma (51) · Lymphoma (50) · Lymphoma, Non-Hodgkin (49) · Lymphoma, Large B-Cell, Diffuse (42) · Myelodysplastic Syndromes (40) · Leukemia, Lymphocytic, Chronic, B-Cell (39) · Lymphoma, Mantle-Cell (39) · Hodgkin Disease (38) · Lymphoma, Follicular (38) · Lymphoma, Large-Cell, Immunoblastic (38) · Lymphoma, B-Cell, Marginal Zone (35) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (32)
Hematologic Diseases (212) · Hemic and Lymphatic Diseases (212) · Immune System Diseases (212) · Lymphatic Diseases (212) · Neoplasms by Histologic Type (212) · Immunoproliferative Disorders (211) · Leukemia, Lymphoid (211) · Lymphoproliferative Disorders (205) · Neoplasms (197) · Leukemia (149) · Leukemia, Myeloid (76) · Pathological Conditions, Signs and Symptoms (75) · Pathologic Processes (74) · Disease Attributes (70) · Bone Marrow Diseases (64)
Cyclophosphamide (67) · Methotrexate (65) · Vincristine (54) · Cytarabine (53) · Dexamethasone (48) · Mercaptopurine (43) · pegaspargase (40) · Doxorubicin (39) · Daunorubicin (36) · Asparaginase (33) · Etoposide (33) · Prednisone (31) · Radiotherapy (30) · Thioguanine (22) · Calcium Dobesilate (21)
Children's Oncology Group (21) · St. Jude Children's Research Hospital (8) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (6) · Fred Hutchinson Cancer Center (6) · Nanfang Hospital, Southern Medical University (6) · National Cancer Institute (NCI) (6) · Institute of Hematology & Blood Diseases Hospital, China (5) · Novartis Pharmaceuticals (5) · Amgen (4) · Assistance Publique - Hôpitaux de Paris (4) · Dana-Farber Cancer Institute (4) · Jonsson Comprehensive Cancer Center (4) · Memorial Sloan Kettering Cancer Center (4) · Alliance for Clinical Trials in Oncology (3)
United States (109) · Canada (44) · Australia (36) · Germany (31) · France (30) · China (28) · Italy (28) · Belgium (23) · United Kingdom (23) · Sweden (19) · Switzerland (19) · Austria (18) · Czechia (18) · Netherlands (18) · Spain (18)
Xiaofan Zhu, MD (4) · Anne L Angiolillo (2) · Dieter Hoelzer, MD,PhD (2) · John A. Glaspy, MD, MPH (2) · Kjeld Schmiegelow, M.D. (2) · Mary Horowitz, MD, MS (2) · Michael G.M. Pfreundschuh, MD (2) · Patrick Stiff, MD (2) · Qifa Liu (2) · Qifa Liu, MD (2) · Sima Jeha, MD (2) · William A. Wegener, MD, PhD (2)
PMID 33242441, PMID 39121442, PMID 37890117, PMID 38446568, PMID 41671463, PMID 15812540, PMID 21195303, PMID 24970932, PMID 25753432, PMID 26590194, PMID 29284596, PMID 31188727, PMID 31612640, PMID 35622074, PMID 36603187, PMID 37341189, PMID 39316653, PMID 40315406, PMID 40908865, PMID 42085640, PMID 10499612, PMID 10627444, PMID 11426549, PMID 11675328, PMID 12111109, PMID 12153596, PMID 12239143, PMID 12694250, PMID 12780755, PMID 15087948, PMID 15154634, PMID 15226337, PMID 15247354, PMID 15256423, PMID 15353542, PMID 15368546, PMID 15459300, PMID 15637138, PMID 15801953, PMID 15952999, PMID 16148284, PMID 16155013, PMID 16421426, PMID 16609069, PMID 16710026, PMID 16877725, PMID 16960978, PMID 17003366, PMID 17039234, PMID 17366834
U10CA098543 (13), U10CA180886 (9), U10CA095861 (4), UG1CA189955 (3), 2014 (2), 2016 (2), 2017 (2), 2025 (2), F32CA141762 (2), P01CA015396 (2), P01CA018029 (2), P30CA006973 (2), P30CA068485 (2), R37CA036401 (2), U01HL069294 (2)